These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 18951988)

  • 1. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
    Pruessmeyer J; Ludwig A
    Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
    Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
    Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved synthesis of ADAM10 inhibitor GI254023X.
    Hoettecke N; Ludwig A; Foro S; Schmidt B
    Neurodegener Dis; 2010; 7(4):232-8. PubMed ID: 20197648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?
    Saftig P; Reiss K
    Eur J Cell Biol; 2011; 90(6-7):527-35. PubMed ID: 21194787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells.
    Schramme A; Abdel-Bakky MS; Kämpfer-Kolb N; Pfeilschifter J; Gutwein P
    Biochem Biophys Res Commun; 2008 May; 370(2):311-6. PubMed ID: 18373975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
    Moss ML; Bomar M; Liu Q; Sage H; Dempsey P; Lenhart PM; Gillispie PA; Stoeck A; Wildeboer D; Bartsch JW; Palmisano R; Zhou P
    J Biol Chem; 2007 Dec; 282(49):35712-21. PubMed ID: 17895248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
    Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
    Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries.
    Tucher J; Linke D; Koudelka T; Cassidy L; Tredup C; Wichert R; Pietrzik C; Becker-Pauly C; Tholey A
    J Proteome Res; 2014 Apr; 13(4):2205-14. PubMed ID: 24635658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening.
    Moss ML; Rasmussen FH
    Anal Biochem; 2007 Jul; 366(2):144-8. PubMed ID: 17548045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.
    Ludwig A; Hundhausen C; Lambert MH; Broadway N; Andrews RC; Bickett DM; Leesnitzer MA; Becherer JD
    Comb Chem High Throughput Screen; 2005 Mar; 8(2):161-71. PubMed ID: 15777180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocytes require ADAM10 but not ADAM17 for their migration and inflammatory recruitment into the alveolar space.
    Pruessmeyer J; Hess FM; Alert H; Groth E; Pasqualon T; Schwarz N; Nyamoya S; Kollert J; van der Vorst E; Donners M; Martin C; Uhlig S; Saftig P; Dreymueller D; Ludwig A
    Blood; 2014 Jun; 123(26):4077-88. PubMed ID: 24833351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolytically active ADAM10 and ADAM17 carried on membrane microvesicles in human abdominal aortic aneurysms.
    Folkesson M; Li C; Frebelius S; Swedenborg J; Wågsäter D; Williams KJ; Eriksson P; Roy J; Liu ML
    Thromb Haemost; 2015 Nov; 114(6):1165-74. PubMed ID: 26422658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells.
    Ebsen H; Schröder A; Kabelitz D; Janssen O
    PLoS One; 2013; 8(10):e76853. PubMed ID: 24130797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth.
    Maretzky T; Schulte M; Ludwig A; Rose-John S; Blobel C; Hartmann D; Altevogt P; Saftig P; Reiss K
    Mol Cell Biol; 2005 Oct; 25(20):9040-53. PubMed ID: 16199880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.
    Mezyk-Kopeć R; Bzowska M; Stalińska K; Chełmicki T; Podkalicki M; Jucha J; Kowalczyk K; Mak P; Bereta J
    Cytokine; 2009 Jun; 46(3):309-15. PubMed ID: 19346138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAM10 as a target for anti-cancer therapy.
    Moss ML; Stoeck A; Yan W; Dempsey PJ
    Curr Pharm Biotechnol; 2008 Feb; 9(1):2-8. PubMed ID: 18289051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha.
    Le Gall SM; Bobé P; Reiss K; Horiuchi K; Niu XD; Lundell D; Gibb DR; Conrad D; Saftig P; Blobel CP
    Mol Biol Cell; 2009 Mar; 20(6):1785-94. PubMed ID: 19158376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
    Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
    Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Antiatherogenic Effect of Fish Oil in Male Mice Is Associated with a Diminished Release of Endothelial ADAM17 and ADAM10 Substrates.
    Speck N; Brandsch C; Schmidt N; Yazdekhasti N; Hirche F; Lucius R; Rimbach G; Stangl GI; Reiss K
    J Nutr; 2015 Jun; 145(6):1218-26. PubMed ID: 25926412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.